Tacrolimus versus anti-tumor necrosis factor agents for steroid-refractory active ulcerative colitis based on the severity of endoscopic findings: a single-center, open-label cohort study

BACKGROUND AND AIMS: At Saitama Medical Center, for remission induction in active ulcerative colitis (UC) patients with endoscopic evidence of severe disease, we tend to preferentially use tacrolimus (TAC) over anti-tumor necrosis factor (TNF)-α agents. We conducted this study to evaluate the validi...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Clin Exp Gastroenterol
Prif Awduron: Matsumoto, Satohiro, Kawamura, Haruna, Nishikawa, Takeshi, Sagihara, Noriyoshi, Miyatani, Hiroyuki, Mashima, Hirosato
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Dove Medical Press 2017
Pynciau:
Original Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5627753/
https://ncbi.nlm.nih.gov/pubmed/29026326
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEG.S143224
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg